The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 17, 2016

Filed:

Dec. 16, 2013
Applicant:

Daiichi Sankyo Company, Limited, Tokyo, JP;

Inventors:

Tsutomu Nagata, Tokyo, JP;

Masahiro Inoue, Tokyo, JP;

Yuka Ashida, Tokyo, JP;

Kengo Noguchi, Tokyo, JP;

Makoto Ono, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/415 (2006.01); C07D 405/12 (2006.01); C07D 233/64 (2006.01); C07D 403/06 (2006.01); C07D 413/06 (2006.01); A61K 31/417 (2006.01); A61K 31/4172 (2006.01); A61K 31/4178 (2006.01); A61K 31/4439 (2006.01); A61K 45/06 (2006.01); C07D 233/90 (2006.01); C07D 401/12 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/08 (2006.01); A61K 9/10 (2006.01); A61K 47/38 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01);
U.S. Cl.
CPC ...
C07D 405/12 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/4866 (2013.01); A61K 9/4875 (2013.01); A61K 31/417 (2013.01); A61K 31/4172 (2013.01); A61K 31/4178 (2013.01); A61K 31/4439 (2013.01); A61K 45/06 (2013.01); A61K 47/38 (2013.01); C07D 233/64 (2013.01); C07D 233/90 (2013.01); C07D 401/12 (2013.01); C07D 403/06 (2013.01); C07D 413/06 (2013.01);
Abstract

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R, R, and Reach independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; Rrepresents a hydrogen atom or a prodrug group; and Y represents —CH—CHR—CH—NHR(wherein Rrepresents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and Rrepresents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.


Find Patent Forward Citations

Loading…